DUBLIN, Dec. 14, 2023 /PRNewswire/ — The “TSLP Pipeline Review” report has been added to ResearchAndMarkets.com’s offering. This product provides basic information on approved drugs and drug candidates in research and development targeting thymic stromal lymphopoietin (TSLP) or its receptor (TSLP-R). Thymic Stromal Lymphopoietin (TSLP) is a cytokine that is a key driver of the inflammatory response… Continue reading Thymic Stromal Lymphopoietin (TSLP) Pipeline Review 2023: Approved Drugs and Drug Candidates in Research and Development
Category: Official Press Release
Global Biopharmaceutical Fermentation Market Analysis Report 2023-2028: Expanding Biosimilars Market, Continuous Fermentation Processes, and Growing Pipeline of Biopharmaceuticals Bolster Growth
DUBLIN, Dec. 14, 2023 /PRNewswire/ — The “Biopharmaceutical Fermentation Market – Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028F” report has been added to ResearchAndMarkets.com’s offering. Global Biopharmaceutical Fermentation Market has valued at USD 24.82 billion in 2022 and is anticipated to project impressive growth in the forecast period with a CAGR of 8.15% through 2028… Continue reading Global Biopharmaceutical Fermentation Market Analysis Report 2023-2028: Expanding Biosimilars Market, Continuous Fermentation Processes, and Growing Pipeline of Biopharmaceuticals Bolster Growth
DMTK DEADLINE TOMORROW: ROSEN, A LEADING LAW FIRM, Encourages DermTech, Inc. Investors to Secure Counsel Before Important December 15 Deadline in Securities Class Action – DMTK
NEW YORK, Dec. 14, 2023 /PRNewswire/ — WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of DermTech, Inc. (NASDAQ: DMTK) between May 3, 2022 and November 3, 2022, both dates inclusive (the “Class Period”), of the important December 15, 2023 lead plaintiff deadline. SO WHAT: If you purchased DermTech securities during… Continue reading DMTK DEADLINE TOMORROW: ROSEN, A LEADING LAW FIRM, Encourages DermTech, Inc. Investors to Secure Counsel Before Important December 15 Deadline in Securities Class Action – DMTK
Global Wilms Tumor Treatment Market Research Report 2023: Rise in Chemotherapy Regimens, Rising Incidence of Wilms Tumor, and Advancements in Surgical Techniques Bolsters Growth – Forecast to 2028
DUBLIN, Dec. 14, 2023 /PRNewswire/ — The “Wilms Tumor Treatment Market – Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028” report has been added to ResearchAndMarkets.com’s offering. Global Wilms Tumor Treatment Market has valued at USD 1.24 billion in 2022 and is anticipated to project robust growth in the forecast period with a CAGR… Continue reading Global Wilms Tumor Treatment Market Research Report 2023: Rise in Chemotherapy Regimens, Rising Incidence of Wilms Tumor, and Advancements in Surgical Techniques Bolsters Growth – Forecast to 2028
Similis revolutioniert die Content-Erstellung mit KI-gestütztem AnyoneSwap
Die neue webbasierte SaaS-Lösung AnyoneSwap tauscht das Gesicht eines Models in Fotos oder Videos mithilfe von KI aus und erzielt dabei eine extrem realistische Produktionsqualität „Faceswapping” mit einem Klick verringert den Zeit- und Kostenaufwand für Bearbeitung oder Neuaufnahme erheblich Automatisches De-Aging für professionellen Touch AnyoneSwap hat das Potenzial, Werbung, Filmproduktionen und die Content-Erstellung für soziale… Continue reading Similis revolutioniert die Content-Erstellung mit KI-gestütztem AnyoneSwap
IKO Announces Brantford Manufacturing Facility
Insulation Plant Expected to Open in 2025 TORONTO, Dec. 14, 2023 /PRNewswire/ – IKO, a global industry leader in the roofing, waterproofing and insulation industry, today announced that it is planning to construct a new manufacturing facility in Brantford Ontario. The new $45 million site will manufacture extruded polystyrene (XPS) insulation, will employ about 30 people in… Continue reading IKO Announces Brantford Manufacturing Facility
LIVENT INVESTS IN ILiAD TECHNOLOGIES TO STRENGTHEN LEADERSHIP IN DIRECT LITHIUM EXTRACTION PRODUCTION PROCESSES
ILiAD to be Licensed and Deployed at Livent’s Resource in Argentina SAN DIEGO, Dec. 14, 2023 /PRNewswire/ — Today, ILiAD Technologies, LLC and Livent Corporation (NYSE:LTHM) announced an agreement whereby Livent has acquired a minority stake in the parent company of ILiAD Technologies. ILiAD Technologies’ parent company is a subsidiary of EnergySource Minerals (ESM), a leading developer… Continue reading LIVENT INVESTS IN ILiAD TECHNOLOGIES TO STRENGTHEN LEADERSHIP IN DIRECT LITHIUM EXTRACTION PRODUCTION PROCESSES
Global Biomaterial Wound Dressing Market Projected to Surge with High CAGR through 2028 Amid Technological Innovations and Increased Demand
DUBLIN, Dec. 14, 2023 /PRNewswire/ — The “Biomaterial Wound Dressing Market – Global Industry Size, Share, Trends Opportunity, and Forecast 2018-2028” report has been added to ResearchAndMarkets.com’s offering. The latest insights into the Biomaterial Wound Dressing Market indicate a notable progression in the industry, with projected growth at an impressive CAGR of 7.05% through 2028… Continue reading Global Biomaterial Wound Dressing Market Projected to Surge with High CAGR through 2028 Amid Technological Innovations and Increased Demand
Offshore Supply Vessel Market to increase by USD 6.00 billion between 2023 to 2028, The Anchor Handling Tug Supply (AHTS) segment will be the largest contributor to market growth – Technavio
NEW YORK, Dec. 14, 2023 /PRNewswire/ — How much is the expected growth in the Offshore Supply Vessel Market size from 2023 to 2028? Continue Reading Technavio has announced its latest market research report titled Global Offshore Supply Vessel Market 2024-2028 The offshore supply vessel market size is expected to grow by USD 6.00 billion… Continue reading Offshore Supply Vessel Market to increase by USD 6.00 billion between 2023 to 2028, The Anchor Handling Tug Supply (AHTS) segment will be the largest contributor to market growth – Technavio
Nona Biosciences Enters into a Global License Agreement with Pfizer for HBM9033, an MSLN-Targeted Antibody-Drug Conjugate (ADC)
Nona Biosciences will receive a total of up to $53 Million in upfront and near-term payments, with the potential for milestones of up to $1.05 billion plus royalties. Pfizer partnership expands Nona’s global network of collaborations, reinforcing its commitment to providing cutting-edge technology innovation to novel therapeutics development. CAMBRIDGE, Mass., Dec. 14, 2023 /PRNewswire/ — … Continue reading Nona Biosciences Enters into a Global License Agreement with Pfizer for HBM9033, an MSLN-Targeted Antibody-Drug Conjugate (ADC)